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Abstract 
Purpose We evaluated the effect of younger age on recurrence risk in Chinese women diagnosed 
with T1N0M0 breast cancer (BC), using propensity score matching (PSM) analysis. 
Methods We included 365 women who were diagnosed with T1N0M0 BC between 2003 and 
2016, and who received surgery at our center. They were classified as younger (≤40 yrs) and 
older (>40 yrs). We used PSM to balance clinicopathologic characteristics between the two age 
groups. Survival was analyzed by the Kaplan–Meier method, before and after PSM.  
Results Over a median follow-up period of 79 months, 54 patients developed recurrences. Before 
PSM, younger patients had worse RFS than older patients. Significantly worse RFS was seen in 
younger patients with HER2+ BC compared with their older counterparts. Younger patients had 
higher rates of loco-regional recurrence rather than metastasis, especially in the first 5 years after 
diagnosis. After PSM, the two age groups still significantly differed in 5-year RFS. 
Conclusion Among PSM pairs with T1N0M0 BC, with equal baselines and treatment conditions, 
we found that patients who presented at younger ages had worse outcomes, independently of 
other pathological features. Younger patients with BC may require more individualized therapy 
to improve their prognosis. 
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Introduction 
In recent years, the epidemiology of breast cancer (BC) among Chinese patients has shown 
intriguing trends. First, age of BC diagnosis is younger among Chinese patients than among 
western women. Hanrahan et al. reported the median age at diagnosis of early-stage BC to be 65 
years among 51,246 patients in the SEER database1, compared with a median age of 49 years in 
a study of 868 Chinese women with stage I–III BC2. Second, the percentage of patients with BC 
who are younger than 40 years old in Western countries is only 5–9.6%3-5, compared with 
approximately 20% in Asian countries6-8.  
The incidence of invasive but node-negative BC with tumors ≤ 2 cm (T1N0M0) has been 
increasing. According to a BC screening program(Chinese National Breast Cancer Screening 
Program ,CNBCSP) among 1.22 million Chinese women, among screening-detected breast 
cancers in urban and rural women, 62.5% and 66.3% were T1 BC, 46.2% and 38.8% were early 
stage(0-I) in urban and rural women respectively9. 
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Generally, the prognosis of T1N0M0 BC is favorable, with a 5-year recurrence-free survival 
(RFS) rate about 90%, even without adjuvant chemotherapy (ACT)1,10,11. However, BC 
recurrence is higher in specific subgroups. Several retrospective studies have described 
prognostic risk factors of T1N0M0 BC, such as human epidermal growth factor receptor 2 
(HER2)-positive, triple-negative BC (TNBC), high Ki-67 index, higher tumor grade and younger 
age1,11-15. Considering the increasing incidence of T1N0M0 BC among younger patients in China, 
survival outcomes among these patients, even with T1N0M0 BC, warrants investigation. 
Therefore, we applied the propensity score matching (PSM) method to assess the impact of age 
on survival outcome from T1N0M0 BC in a Chinese cohort.  
Materials and Methods  
Study population  
We retrospectively identified patients with T1N0M0 BC who received surgery between 2003 and 
2016 in Sun Yat-sen Memorial Hospital Breast Cancer Center. Eligibility criteria included (1) 
pathologic diagnosis of T1N0M0 tumor; (2) unilateral BC; and (3) invasive ductal and lobular 
carcinoma. Patients who (1) received any kind of neoadjuvant therapy; (2) received breast-
conserving surgery (BCS) but without radiotherapy; or (3) had multifocal tumors detected by 
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mammography, ultrasonography and/or magnetic resonance imaging were excluded from this 
analysis. Finally, 365 T1N0M0 cases were enrolled. All eligible patients received surgical 
treatment and ACT based on tumor size and pathologic characteristics, according to NCCN 
guidelines and patients’ preference. In our center, adjuvant HER2-targeted therapy was routinely 
recommended for patients with T1cN0 HER2+ BC, but not for those patients with T1a–bN0 
HER2+ BC. Sentinel lymph node biopsy (SLNB) was recommended in principle for all included 
patients but axillary lymph node dissection (ALND) was performed if the patient refuse to receive 
SLNB or if SLNB failed. Full ethical approval was granted by Sun Yat-Sen Memorial Hospital 
Ethics Committee (SYSEC-KY-KS-2018-044).  
Data  
We collected prospectively registered medical records from the Research Electronic Data 
Capture system. We divided patients according to their ages at diagnosis into the younger group 
( ≤40 yrs) and the older group (> 40 yrs). For each patient, we retrieved all information on tumor 
size, lymph node status, histological type, tumor grade, hormonal receptor (HR) status, HER2 
status, Ki-67 expression, surgery type and adjuvant therapy. All enrolled patients had been tested 
for HER2 status according to the testing guideline at the time of diagnosis. Patients who were 
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diagnosed during 2003–2006 were tested according to the Herceptest® Scoring System16,17; 
those diagnosed during 2007–2012 were tested according to the 2007 ASCO/CAP guideline18; 
and those who diagnosed during 2013–2016 were tested according to the 2013 ASCO/CAP 
guideline19. 
Estrogen receptors (ER) and progesterone receptors (PR) were considered positive when nuclear 
expression was observed in at least 1% of the tumor cells. For Ki-67 status, we used ≥14% 
positive staining as the cut-off for positive and negative results. We classified BC cases into 3 
subgroups: HR+ (ER/PR+, HER2−) , HER2+ (HER2+, regardless of ER/PR status) and TNBC 
(ER−,PR−, HER2−).  
Statistical Methods  
Patient characteristics were tabulated and described by median and range. Comparisons between 
groups were made using the χ2 test. RFS was defined as interval between the date of diagnosis 
and the first local or distant disease recurrence or contralateral breast event, or the last follow-up 
without relevant event, which was further divided into locoregional recurrence-free survival and 
distant recurrence-free survival. Patients who died before disease recurrence were considered 
censored at the date of death. Patients who experienced both local and distant recurrences at the 
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same time were considered to have suffered both events. RFS was estimated by the Kaplan–
Meier method. The log-rank test was used to compare survival curves between subgroups 
according to prognostic factors. All statistical tests were two-sided; P < 0.05 was considered 
significant.  
Propensity score matching  
Propensity scores (PS) were generated from a logistic regression model described by Rosenbaum 
and Rubin20. Covariates, including tumor size, tumor grade, subtype, Ki-67 expression, breast 
surgery type and ACT, were selected into the model as reported risk factors to optimize the 
matching procedure by reducing bias for mortality and recurrence1,11-15,21,22. Due to the definition 
of HER2+ group (HER2+, regardless of HR status), the percentage of patients with HR+ disease 
(ER+ or PR+, regardless of HER2 status) who needed endocrine therapy was different in the two 
age groups. However, endocrine therapy did not significantly differ among patients with HR+ 
disease between the two age groups before and after PSM (Supplementary Table 2). Therefore, 
to match more pairs, adjuvant endocrine therapy (AET) was not analyzed in the PSM procedure. 
In this retrospective study, each patient in the younger group was 1:1 matched, with caliper value 
of 0, to a corresponding patient in the older group by selecting the same PS for each pair. Both 
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Kaplan–Meier method and the exact method of McNemar’s test were used to compare the 
survival of the two groups. All statistical analyses were performed by SPSS, version 24.0. 
Results 
Clinicopathologic characteristics  
The median age of the 365 participating women was 50 years, of whom 17% (62/365) were in 
the younger group (median age: 37 years, range: 26–40 years) and 83% (303/365) were in the 
older group (median age: 52 years, range: 41–78 years). Their clinicopathological characteristics 
are shown in Table 1. The younger group tended to have higher Ki-67 expression (P =0.016) and 
higher tumor nuclear grade (P =0.099). The younger group also showed a trend for higher rates 
of HER2+ (19.4% vs. 15.8%) and TNBC tumors (14.5% vs. 9.0%), although without statistical 
significance. Of the 365 participants, 245 (67.1%) underwent BCS with radiotherapy and 120 
(32.9%) underwent mastectomies. Because the study only included patients with lymph node-
negative disease, no patients who underwent mastectomies received radiation for negative 
axillary lymph node. Younger patients tended to have lower compliance to the AET than older 
patients (74.2% vs. 83.2%, P=0.096). Among patients with HR+ tumors (312/365), 90.2% 
(46/51) of the younger patients and 96.5% (252/261) of the older patients received AET 
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(Supplementary Table 2), and 314 patients (86.0%) received ACT. Among the 60 patients with 
HER2+ tumors (T1a–bN0: n=20, T1cN0: n=40), 53.3% (32/60) of HER2+ patients with T1cN0 
tumors received standard one-year adjuvant trastuzumab therapy; 13.4% (8/60) of patients with 
T1cN0 tumors only received adjuvant trastuzumab therapy for half a year, due to financial issues; 
and 33.3% (20/60) patients were not recommended to undergo adjuvant HER2 targeted therapy 
for T1a–bN0 tumors. Younger patients were more likely to have BCS with radiotherapy than 
older patients (77.4% vs 59.1%, P =0.058). 
Recurrence and prognosis before PSM  
For the cohort as a whole, median follow-up was 79 months (range: 13–125 months); both 5-
year OS (96.6%) and 10-year OS (94.0%) were very favorable. However, 54 patients experienced 
recurrences, including 24 locoregional recurrences, 28 distant metastases, 6 contralateral breast 
events and 4 patients with both locoregional and distant recurrences. Kaplan–Meier survival 
curves showed younger patients had a significant lower 5-year RFS rate (younger: 80.6%, older: 
89.1%, P =0.049; Figure 1). When stratified by site and time of recurrence(Table 2), younger age 
was associated with significantly higher rates of all recurrences and locoregional recurrences 
(14.5% vs 5.0%, P =0.004), but not with distant recurrences (younger: 6.5%, older: 7.9%, P 
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=0.795) or contralateral breast events (younger: 6.5%, older: 0.7%, P =0.229). Younger patients 
had a significantly higher rate of recurrence for Years 0–5 than older patients, but not for Years 
5–10.  
Survival analysis based on subtypes and age showed that younger patients with the HER2+ 
subtypes had worse RFS than older patients (P =0.006), but did not significantly differ in RFS 
for those with HR+ BC (P = 0.845) or TNBC (P =0.390). The subgroup with the worst 5-year 
RFS estimate were younger patients with HER2+ tumors (50.0%; Table 3).  
Recurrence and prognosis after PSM 
After PSM, we had 60 pairs (60 younger patients and 60 older patients) from 62 younger patients 
and 303 older patients; the two members of each pair were consistent in the above 6 matching 
covariates except age (Table 1). Among the 60 younger patients after PSM, 12 had recurrence 
events within 5 years. The other 48 patients showed no recurrences over ≥5 years of follow-up 
visits. Follow-up periods and outcomes of patients before and after PSM are shown in 
Supplementary Table 1. For patients whose BC recurred within 5 years, although they were not 
followed up for 5 years, as long as their paired patients survived over 5 years, these pairs were 
comparable. However, 5-year RFS still significantly differed between the age groups (younger: 
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80.0%, older: 96.7%, P =0.015; Figure 2) after PSM. Then, as the samples were matched into 
pairs, the paired chi-square test (McNemar's test) was used to unravel the impact of age on 5-
year survival in a paired sample unit. In Table 4, for 46 pairs, outcomes of the two age members 
were similar (survived for ≥5 years without recurrence); in no pairs did both members relapsed 
within 5 years. However, for 14 pairs (12+2), outcomes of the two age members were different. 
The McNemar’s test was applied to the 14 outcome-discordant pairs to figure out if younger 
members of the pairs were significantly more likely to relapse within 5 year than the older 
members. We found that the younger members of the pairs were significantly more likely to 
relapse within 5 years than the older members (P=0.013), which shows the effect of age on 
prognosis. 
Discussion  
The major finding of this retrospective study is that after using PSM to adjust for a series of 
clinicopathologic features and treatment strategy, age ≤40 years at presentation is an independent 
prognostic risk factor, associated with worse 5-year RFS rates in patients with T1N0M0 BC, and 
particularly so for younger patients with HER2+ T1N0M0 BC. 
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In previous studies of prognostic risk factors (including age) for T1N0M0 BC, patients who 
received ACT were often excluded from analyses12,23. However, as NCCN guidelines 
recommend ACT with or without target therapy for T1b–c patients, excluding patients treated 
with ACT cannot reflect the real-world impact of age on prognosis. In our study cohort, 86% 
patients received ACT. By including ACT as a PSM variate, the impact of age on survival was 
more accurately estimated. Our results indicate that younger BC patients have a worse prognosis, 
independent of other factors associated with aggressiveness, including HER2 status, even among 
patients with T1N0M0 disease. However, NCCN guidelines for T1N0M0 BC treatment are only 
based on tumor size and subtype; younger patient age is not among the recommended criteria for 
choosing a treatment strategy. Breast cancer in younger women is an aggressive disease, even for 
those with T1N0M0 BC, thus, individualized treatment should be considered, especially in Asian 
populations, which have a higher percentage of younger patients with T1N0M0 BC. Anders et al 
suggests that younger women can be characterized by lower hormone sensitivity and higher 
HER2 expression by using genomic expression analysis24 which might explain the poor 
prognosis. Also, Johnson et al found expression differences in age-related genes (KRT5, KRT6A, 
KRT6B and EGFR) within and across BC subtypes, which were significantly associated with 
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inferior prognosis in younger women25. Together, these findings highlight the need to re-examine 
treatment strategies for younger patients with T1N0M0 BC.  
In subtype analysis, we observed a significantly worse 5-year RFS for younger women diagnosed 
with HER2+ BC compared with their older counterparts (50.0% vs. 85.4%, P =0.006). However, 
because of the small numbers of patients, this point estimate has a wide confidence interval. A 
previous study suggested that trastuzumab-based ACT may reduce both early recurrence and 
mortality in HER2+ tumors that are ≤ 1 cm12, although many clinicians might not recommend 
ACT in view of the small benefit balanced against costs and toxicity10. A study of outcomes of 
1102 patients with T1a–bN0M0 BC showed that patients <35 years old with HER2+ tumors had 
the worse 5-year RFS23. This result is consistent with our research, which suggests that age 
should be considered when deciding on adjuvant therapy for HER2+ T1N0M0 BC; these patients 
may be more likely to benefit from trastuzumab-based ACT. According to the NCCN guidelines, 
cyclophosphamide (C) plus trastuzumab (T) is recommended for T1c HER2+ rather than T1a–b 
tumors. Our results indicate that patients younger than 40 years old with HER2+ had a higher 
rate of recurrence. Therefore, prospective clinical trials are needed to find a regimen that delivers 
the optimal survival benefit with fewer adverse reactions for this population. However, the effect 
 15 
of age on HR+ tumors was not significant. Some studies suggested that although younger women 
had high rates of AET, nonadherence may have led to inadequate treatment efficacy in younger 
women and contribute to poor outcomes for HR+ patients26,27. In our cohort, 96% HR+ women 
received AET, and even younger patients achieved more than 90% compliance to the treatment. 
Good adherence to treatment may reduce the poor effects of age on prognosis. Among patients 
with TNBC, we observed no difference between the two age groups. Ford et al. observed that 
5.3 % of BCs in patients ≤40 years old were attributable to BRCA1 mutations, compared with 
2.2% in 40–49 year-olds and 1.1 % in 50–70 year-olds28. Patients with BRCA1 mutations were 
more likely to develop basal-like BCs, including the triple-negative subtype29,30. The underlying 
biology may help explain the relationship between age and TNBC.  
We also found that, before PSM, younger patients had significantly higher rates of the 
locoregional recurrence rather than metastasis in the first five year after diagnosis. In recent years, 
comprehensive therapy have helped improve local control after breast-conserving surgery, 
although the local recurrence rate for younger patients who undergo BCS was significantly higher 
than that of those undergo mastectomy22. In our cohort, 245/365 (67.1%) of women received 
BCS and the percentage of younger patients received BCS was higher than older patients (48/62 
 16 
[77.4%] vs. 197/303 [59.1%]). A meta-analysis of 19 studies included showed that after BCS, 
younger BC patients are at higher risk of local recurrence within 5 years (RR: 2.64, 95% CI: 
1.94–3.60) and 10 years RR: 2.37, 95% CI: 1.57–3.58) than older patients31. Several factors may 
contribute to locoregional recurrence for younger women. First, whereas preoperative imaging 
of multifocal tumors can help identify choose optimal surgical approaches, a higher percentage 
of younger patients have higher mammographic density than do older patients32, which may 
decrease mammographic sensitivity (masking bias); this effect seems to be more obvious in small 
tumors33. However, digital mammography, ultrasonography, and magnetic resonance imaging 
may increase cancer detection in women with high mammographic density. Although multifocal 
tumors were excluded from our study, the relationship between preoperative imaging assessment 
and recurrence rate after BCS in younger patients with T1N0M0 BC warrants further study. 
Furthermore, studies that use gene expression micro-array technology have demonstrated 
patterns that correlate with local recurrence in younger women34. However, data on related genes 
were not available in our material. In addition, the relatively short follow-up period may not be 
sufficient to observe differences in long-term locoregional recurrence and metastasis between the 
two age groups. 
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Our study had several limitations. First, it was a retrospective single-institution study, which lent 
inherent bias. Second, during the study period of 13 years, continuous optimization of treatment 
regimens may have varying effects on prognosis of the two age groups. Third, other important 
information, such as Oncotype DX and MammaPrint were not available. However, after 
adjusting for known prognostic factors using PSM, our results suggested that recurrence in 
women younger than 40 years old with T1N0M0 BC were significantly higher than for older 
patients. Few studies of preoperative imaging evaluation, surgery selection and postoperative 
therapy for younger patients with T1N0M0 BC are available. Studies based on genetic 
information and a larger sample size are therefore needed to evaluate the effect of age on 
prognosis. 
Conclusions  
Among patients with T1N0M0 BC, age of 40 years or younger is a prognostic risk factor 
independent from other aggressive features, including HER2 status. We found the recurrence rate 
for younger patients with T1N0M0 BC to be significantly higher than for older patients, 
especially for those with the HER2+ subtype. Therefore, treatment decisions for T1N0M0 BC 
should consider age as a prognostic factor together with subtype and other tumor characteristics. 
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Younger T1N0M0 patients might benefit more from more comprehensive evaluation and 
individualized treatment.  
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Figure legends 
Figure 1 Recurrence-free survival by age at diagnosis before PSM; 
Figure 2 Recurrence-free survival by age at diagnosis after PSM. 
Abbreviations and acronyms used in the figure 
PSM propensity score matching  
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Table 1. Patient characteristics by age of diagnosis, before and after aPSM 
Characteristics ≤40yrs >40yrs P Characteristics ≤40yrs >40yrs P 
 before PSM n=62 17.0(%) n=303 83.0(%)   after PSM n=60 50(%) n=60 50(%)   
Subtype           Subtype           
bHR+ (n=269,73.7%) 41 66.1  228 75.2    bHR+ (n=82,68.3%) 41 68.3  41 68.3    
cHer-2+ (n=60,16.4%) 12 19.4  48 15,8   cHer-2+ (n=24,20.0%) 12 20.0  12 20.0    
dTNBC (n=36,9.9%) 9 14.5  27 9.0  0.272 dTNBC (n=14,11.7%) 7 11.7  7 11.7  1.000  
Histology            Histology            
Ductal (n=320,87.7%) 56 90.3  264 87.1    Ductal (n=108,90.0%) 55 91.7  53 88.3    
Lobular (n=45,12.3%) 6 9.7  39 12.9  0.486 Lobular (n=12,10.0%) 5 8.3  7 11.7  0.543  
T-stage           T-stage           
T1a-1b (n=103,28.2%) 21 33.8  82 27.1    T1a-1b (n=38,31.7%) 19 31.7  19 31.7    
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T1c (n=262,71.8%) 41 66.2  221 72.9  0.278 T1c (n=82,68.3%) 41 68.3  41 68.3  1.000  
Grade           Grade           
I-II (n=288,62.4%) 33 53.2  195 64.4    I-II (n=66,55.0%) 33 55.0  33 55.0    
III (n=137,37.6%) 29 46.8  108 35.6  0.099 III (n=54,45.0%) 27 45.0  27 45.0  1.000  
Ki-67           Ki-67           
<14% (n=105,28.8%) 10 16.1  95 31.4    <14% (n=20,16.7%) 10 16.7  10 16.7    
≥14% (n=260,71.2%) 52 83.9  208 68.6  0.016 ≥14% (n=100,83.3%) 50 83.3  50 83.3  1.000  
Surgery Type           Surgery Type           
eBCS+fRT (n=245,67.1%) 48 77.4  197 59.1    eBCS+fRT (n=84,70.0%) 47 78.3  47 78.3    
Mastectomy (n=120,32.9%) 14 22.6  106 40.9  0.058 Mastectomy (n=36,30.0%) 13 21.7  13 21.7  1.000  
gSLNB only (n=293,80.3%) 54 87.1  239 78.9    gSLNB only (n=97,80.8%) 52 86.7  45 75.0    
hALND (n=72,19.7%) 8 12.9  64 21.1  0.138 hALND (n=23,19.2%) 8 13.3  15 25.0  0.104  
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Adjuvant Endocrine therapy      Adjuvant Endocrine therapy      
Yes(n=298,81.6%) 46 74.2 252 83.2  Yes(n=90,75.0%) 46 76.7 44 73.3  
No(n=67,18.4%) 16 25.8 51 16.8 0.096 No(n=30,25.0%) 14 23.3 16 26.7 0.673 
Adjuvant chemotherapy           Adjuvant chemotherapy           
Yes(n=314,86.0%) 57 92.0  257 84.8    Yes (n=110,91.7%㸧 55 91.7  55 91.7    
No(n=51,14%) 5 8.0  46 15.2  0.141 No (n=10,8.3%) 5 8.3  5 8.3  1.000  
Abbreviations: 
a. PSM: propensity score matching 
b. HR+: ER+ or PR+, HER2− 
c. Her-2 +: ER+ or ER−, PR+ or PR− 
d. TNBC:ER−,PR−, HER2− 
e. BCS: breast-conserving surgery   
f. RT: radiotherapy 
g. SLND: sentinel lymph node biopsy 
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h. ALND: axillary lymph node dissection 
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a. Four patients had both locoregional and distant recurrence at same time 
 
Table 2. Recurrence for both age groups by site and time of recurrence 
  All patients Age groups Log-rank 
      n=365 ≤40yrs(n=62) >40yrs(n=303) P-value  
All recurrence, n (%) 54 (14.8) 14 (22.6) 40 (13.2) 0.049 
aSite of recurrence, n (%)             
Locoregional recurrence 24 (6.6) 9 (14.5) 15 (5.0) 0.004 
Distant recurrence 28 (7.7) 4 (6.5) 24 (7.9) 0.795 
Contralateral breast event 6 (1.6) 4 (6.5) 2 (0.7) 0.229 
Time of Recurrence, n (%)             
0-5 years 45 (12.3) 12 (19.4) 33 (10.9㸧 0.034 
5-10 years 9 (2.5) 2 (3.2) 7 (2.3㸧 0.493 
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Table 3. Recurrence-free survival by age groups and breast cancer subtype  
Subtype Age groups Patients at risk (n)  Recurrence (n)  5-Year deRFS(95% CI) P-value 
aHR+ ≤40yrs 41 4 90.2 (0.812, 0.992)   
  >40yrs 228 26 91.2 (0.875, 0.949) 0.845  
bHer-2+ ≤40yrs 12 6 50.0 (0.218, 0.782)   
  >40yrs 48 7 85.4 (0.754, 0.954) 0.006  
cTNBC ≤40yrs 9 4 70.8 (0.436, 0.980)   
  >40yrs 27 7 77.3 (0.612, 0.934) 0.390  
Abbreviations: 
a. HR+: ER+ or PR+, HER2− 
b. HER2+: HER2+, ER+ or ER−, PR+ or PR− 
c. TNBC: ER−, PR−, HER2− 
d. eRFS: estimated recurrence-free survival 
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Table 4. A 2*2 Contingency table, using matched pairs (n=60) as the sampling units  
  Outcome of patients >40yrs (pairs)    
Outcome of patients ≤40yrs (pairs) Did not recur for 5yrs Recurred within 5yrs Total(n) P-value 
Did not recur for 5yrs 46 2 48  
Recurred within 5yrs 12 0 12  
Total(n) 58 2 60 0.013 
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Supplementary Table 1 Outcome and follow-up time by age of diagnosis before and after aPSM 
 
 
Abbreviations: 
a. PSM: propensity score matching 
b. RFS: Recurrence-free survival (The interval between the date of diagnosis and the first local or distant disease recurrence, or contralateral breast 
recurrences event, or the last follow-up without relevant event). 
 
Characteristics 
≤40yrs 
(n=62,17.0%) 
>40yrs 
 (n=303,83.0%) Characteristics 
≤40yrs 
( n=60,50%) 
>40yrs 
 n=(60,50%) 
 
Before PSM 
 
 
Recurred 
within 5yrs 
㸦n=13㸧 
Did not recur 
for 5yrs 
㸦n=49㸧 
Recurred 
within 5yrs 
㸦n=33㸧  
Did not recur 
for 5yrs 
㸦n=270㸧  
 
After PSM 
 
 
Recurred  
within 5yrs
㸦n=12㸧 
Did not recur  
for 5yrs 
㸦n=48㸧  
Recurred  
within 5yrs 
㸦n=2㸧 
Did not recur 
for 5yrs
㸦n=58㸧 
Follow-up(bRFS)     Follow-up(RFS)     
<5yrs 13 0 33 2 <5yrs 12 0 2 0 
≥5yrs 0 49 0 268 ≥5yrs 0 48 0 58 
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Supplementary Table 2 Adjuvant endocrine therapy among HR-positive patient by age of diagnosis before and after aPSM 
bHR-positive ≤40yrs(n=62) >40yrs(n=303) cP HR-positive ≤40yrs(n=60) >40yrs(n=60) cP 
 before PSM n=51 
82.2(%
) 
n=26
1 
86.1(%
)   after PSM 
n=5
1 
85.0(%
) 
n=4
8 
80.0(%
)   
Adjuvant endocrine 
therapy           
Adjuvant endocrine 
therapy           
Yes(n=298,95.5%) 46 90.2 252 96.5   Yes(n=90,90.9%) 46 90.2 44 91.7   
No(n=14,4.5%) 5 9.8 9 3.5 0.102 No(n=9,9.1%) 5 9.8 4 8.3 
1.00
0  
 
Abbreviations: 
a. PSM: propensity score matching 
b. HR positive group: ER+ or PR+, HER2− or HER2+) 
c. P for Continuity Correction       
 
 
